A Multi-Center, Open Label, Phase I, Dose Finding and Expansion Study of RO7051790 Administered Orally in Patients With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs RG 6016 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 05 Dec 2017 Status changed from active, no longer recruiting to completed.
- 23 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2017 According to an Oryzon media release, Roche is planning to finalize this trial in the following months.